Insider Buying: Tyra Biosciences (NASDAQ:TYRA) Director Acquires $20,003.76 in Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Rehan Verjee acquired 972 shares of the business’s stock in a transaction dated Wednesday, September 9th. The shares were acquired at an average price of $20.58 per share, for a total transaction of $20,003.76. Following the acquisition, the director directly owned 972 shares in the company, valued at $20,003.76. This represents a ? increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

Tyra Biosciences Stock Performance

Shares of TYRA opened at $22.03 on Monday. The stock has a 50 day simple moving average of $28.39 and a 200 day simple moving average of $31.83. Tyra Biosciences, Inc. has a 52-week low of $11.82 and a 52-week high of $40.65. The firm has a market capitalization of $1.31 billion, a PE ratio of -9.18 and a beta of 0.73.

Tyra Biosciences (NASDAQ:TYRA) last announced its earnings results on Tuesday, August 4th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.04). Equities research analysts predict that Tyra Biosciences, Inc. will post -2.74 EPS for the current fiscal year.

Trending Headlines about Tyra Biosciences

Here are the key news stories impacting Tyra Biosciences this week:

• Positive Sentiment: Initial SURF302 results support further development of dabogratinib in bladder cancer, providing evidence of potential activity for Tyra’s lead program. The Pharma Letter article
• Positive Sentiment: Wedbush reaffirmed its “Outperform” rating and maintained a $53 price target, signaling substantial potential upside if the clinical program succeeds. Benzinga analyst rating report
• Positive Sentiment: Director Rehan Verjee purchased 972 shares for approximately $20,004 at an average price of $20.58. The insider purchase may be viewed as a signal of confidence, although its size is modest relative to the company’s market value. SEC insider ownership filing
• Neutral Sentiment: Reported short-interest data showed zero shares sold short and a zero-day short-interest ratio, but the figures appear anomalous and provide little useful information about trading sentiment.
• Negative Sentiment: Coverage indicated that bladder-cancer response rates from SURF302 were below investor expectations, creating uncertainty about dabogratinib’s commercial and regulatory potential. BioSpace article
• Negative Sentiment: HC Wainwright lowered its price target from $45 to $30, although it retained a “Buy” rating, reflecting reduced near-term expectations following the trial update. Benzinga analyst rating report
• Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of TYRA investors, adding a legal and reputational overhang. The announcement did not establish wrongdoing by Tyra. Pomerantz investor alert

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on TYRA shares. Piper Sandler reaffirmed an “overweight” rating and issued a $56.00 price objective on shares of Tyra Biosciences in a research report on Tuesday, September 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tyra Biosciences in a report on Friday, July 17th. HC Wainwright dropped their price target on Tyra Biosciences from $45.00 to $30.00 and set a “buy” rating on the stock in a research note on Thursday. Cantor Fitzgerald reissued an “overweight” rating on shares of Tyra Biosciences in a research note on Thursday. Finally, Wolfe Research started coverage on Tyra Biosciences in a report on Tuesday, May 19th. They issued a “peer perform” rating on the stock. Eleven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $47.88.

Institutional Investors Weigh In On Tyra Biosciences

Large investors have recently made changes to their positions in the stock. Walleye Capital LLC bought a new stake in Tyra Biosciences during the second quarter worth $11,112,000. 5AM Venture Management LLC bought a new position in shares of Tyra Biosciences in the 2nd quarter valued at about $32,875,778. Seven Fleet Capital Management LP grew its position in shares of Tyra Biosciences by 149.6% in the 1st quarter. Seven Fleet Capital Management LP now owns 198,585 shares of the company’s stock valued at $7,606,000 after acquiring an additional 119,025 shares during the period. Bank of America Corp DE increased its stake in shares of Tyra Biosciences by 448.0% during the 1st quarter. Bank of America Corp DE now owns 209,922 shares of the company’s stock worth $8,040,000 after purchasing an additional 171,612 shares during the last quarter. Finally, Jupiter Topco LLC acquired a new position in shares of Tyra Biosciences during the 2nd quarter worth about $139,161,000. Institutional investors and hedge funds own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc is a clinical-stage biotechnology company focused on developing precision medicines for diseases with limited treatment options. The company uses its proprietary SNÅP platform to design small-molecule therapies intended to selectively target disease-driving genetic alterations while addressing resistance mechanisms that can reduce the effectiveness of existing treatments.

Tyra’s lead programs are directed at fibroblast growth factor receptor (FGFR) biology. TYRA-300 is an oral, selective FGFR3 inhibitor being developed for conditions including FGFR3-altered urothelial cancer and achondroplasia, a genetic skeletal disorder.